Integrins are a superfamily of transmembrane cell surface receptors that mediate signal transduction, cell-to-cell interaction, and cell-to-extracellular matrix adhesion - key processes for healthy cells as well as progression of disease states such as atherosclerosis and cancer, where integrins contribute to angiogenesis, tumorigenesis, and metastasis.
Among this superfamily, αvβ3 integrin holds promise as a therapeutic target in areas such as immuno-oncology, where αvβ3 integrin may prevent tumors from evading the immune system. PerkinElmer's IVISsense™ Integrin Receptor fluorescent probes (IntegriSense™) are designed to target αvβ3 integrin for monitoring tumor growth, angiogenesis and assessing treatment efficacy.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IVISense Integrin Receptor 645 fluorescent imaging probe for in vivo detection of αvβ3 integrin is a low molecular weight peptidomimetic antagonist coupled to a red fluorochrome. This validated, high affinity (Kd = 4.2 nM) fluorescent probe has improved circulation half-life and specificity over RDG peptide-based agents, with selectivity 5-20x for αvβ3 integrin, for precise detection of αvβ3 integrins. This integrin-targeted molecular imaging probe enables non-invasive imaging to better understand biological processes, and disease biology and progression.
Including IVISense Integrin Receptor 645 fluorescent agent in careful experimental design allows for multiplexing with other channels and/or imaging times, and can be paired with other probes to achieve maximum efficiency and flexibility in your imaging studies.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Angiogenesis, Atherosclerosis, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||645 nm|
Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles asso ...
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And ...
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best p ...
Integrins are a superfamily of transmembrane cell surface receptors that mediate signal transduction, cell-to-cell interaction, and cell-to-extracellular matrix adhesion - key processes for healthy cells as well as in the progression of disease states such as cancer.
Among this superfamily, ...
The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.
This s ...
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick ...